G. Mondragon-Ramirez

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al. · American Journal of Transplantation · 2010 · 946 citations

Medicine, Nephrology, Pharmacology +15

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

Flavio Vincenti, Christian P. Larsen, Josefina Alberú et al. · American Journal of Transplantation · 2011 · 308 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study

Lionel Rostaing, Flavio Vincenti, J.M. Grinyó et al. · American Journal of Transplantation · 2013 · 189 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study

Bernhard K. Krämer, B Charpentier, Lars Bäckman et al. · American Journal of Transplantation · 2010 · 166 citations · Full text

Medicine, Nephrology, Pharmacokinetics +12

Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years

Janette Furuzawa‐Carballeda, Norma Uribe‐Uribe, José Manuel Arreola‐Guerra et al. · Clinical & Experimental Immunology · 2019 · 12 citations · Full text

Life Sciences, Immunology, Pathology +17